Vaccine最新文献

{"title":"COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.","authors":"Sylvia Kusemererwa, Violet Ankunda, Terry A Ongaria, Andrew Abaasa, Ayoub Kakande, Deogratius Ssemwanga, Geofrey Kimbugwe, Bernadette Nayiga, Henry K Bosa, Alfred Driwale, Yonas T Woldemariam, Annet Kisakye, James Humphreys, Archibald K Worwui, Sandra Cohuet, Jason M Mwenda, Alison M Elliott, Pontiano Kaleebu, Eugene Ruzagira","doi":"10.1016/j.vaccine.2025.126984","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.126984","url":null,"abstract":"<p><strong>Introduction: </strong>The emergence of new SARS-CoV-2 variants threatens the effectiveness of global vaccination campaigns. This study examines the vaccination status and associated factors among patients presenting with COVID-19-like symptoms at 19 healthcare facilities in Uganda.</p><p><strong>Materials and methods: </strong>A cross-sectional analysis was conducted using data collected at health facilities to evaluate the effectiveness of COVID-19 vaccines in Uganda from March 2023 to March 2024. Participants were individuals aged 12 years and older with COVID-19-like symptoms who underwent a SARS-CoV-2 qPCR test within 10 days of symptom onset. The study involved obtaining informed consent, collecting medical and vaccination histories (confirmed using vaccination cards and Ministry of Health COVID-19 database), performing physical examinations, administering a questionnaire, and taking oral/nasopharyngeal swabs for SARS-CoV-2 qPCR testing. Vaccination coverage was defined as receiving at least one vaccine dose. Logistic regression was used to identify factors associated with vaccination status.</p><p><strong>Results: </strong>Among 1398 participants enrolled (55.4 % female), the median age was 30.0 years (IQR: 24.0-41.0). Vaccination coverage, was 66.6 %. Residing in Wakiso district compared to the Capital, Kampala was associated with a higher likelihood of vaccination (adjusted odds ratio [aOR] = 1.4, 95 % CI: 1.0-1.8, p = 0.021). Frontline and healthcare workers were more likely to be vaccinated (aOR = 5.0, 95 % CI: 3.6-7.3, p < 0.001), as were individuals with a previous COVID-19 diagnosis (aOR = 2.4, 95 % CI: 1.6-3.9, p < 0.001).</p><p><strong>Conclusions: </strong>Our results underscore the need for targeted public health messaging and support to promote vaccination, especially among non-healthcare workers. Addressing these gaps is crucial for maintaining high vaccination coverage and mitigating the impact of new SARS-CoV-2 variants on the population.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126984"},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.","authors":"Brian O Onyando, Bryan O Nyawanda, Daniel Onguru, Fadima C Haidara, Collins Okello, Raphael O Anyango, Ian K Orege, Sidney Ogolla, Billy Ogwel, Alex O Awuor, Samuel Kadivane, Philip Ngere, Carolyne Nasimiyu, Eric Osoro, M Kariuki Njenga, Victor Akelo, Amos Otedo, Shirley Lidechi, John B Ochieng, Nancy A Otieno, Erick M O Muok, Kibet Sergon, Archibald Kwame Worwui, Goitom G Weldegebriel, Isabel Bergeri, Cohuet Sandra, Celine Gurry, J Pekka Nuorti, Patrick Amoth, Rose Jalang'o, Jason M Mwenda, Richard Omore, Samba O Sow","doi":"10.1016/j.vaccine.2025.126910","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.126910","url":null,"abstract":"<p><strong>Background: </strong>Mortality attributed to respiratory illnesses is well characterized in children <5 years. However, there is paucity of data among older populations. Here, we leveraged data from the COVID-19 Vaccine Effectiveness Evaluation to establish the factors associated with mortality among patients with severe respiratory illness (SRI) in Kenya and Mali.</p><p><strong>Methods: </strong>We enrolled patients (≥ 12 years) requiring hospitalization for SRI, defined as acute onset (≤ 14 days) of at least two of the following: cough, fever (reported/measured temperature of ≥38 °C), chills, rigors, myalgia, headache, sore throat, fatigue, congestion or runny nose, loss of taste or smell, or pneumonia diagnosis, from referral hospitals in Kenya and Mali. We collected demographic, clinical characteristics of the patients, and nasopharyngeal and oropharyngeal specimens for SARS-CoV-2 testing using RT-PCR. A mixed-effects logistic regression model was fitted to identify factors associated with 30-day mortality among patients with SRI.</p><p><strong>Results: </strong>Between July 2022 and October 2023 9947 SRI patients were enrolled, of whom 9743 were included in this analysis and 1620 (16.6 %) died (Kenya: 1533/7822 [20.0 %]; Mali: 87/1921 [4.5 %]). Compared to patients aged 12-24 years, those aged >64 years were more likely to die (adjusted Odds Ratio [aOR] = 2.36; 95 % Confidence Interval [95 % CI] 1.72-3.24). Patients who were in coma (aOR = 3.45; 95 %CI 2.27-5.24) or Intensive Care Unit (aOR = 2.98; 95 %CI 2.06-4.31), or had HIV infection (aOR = 2.47; 95 %CI 2.11-2.90), liver disease (aOR = 2.42; 95 %CI 1.57-3.74), cancer (aOR = 2.09; 95 %CI 1.46-2.99) or SARS-CoV-2 infected (aOR = 1.24; 95 %CI 1.02-1.52) were at increased risk of death. Additionally, diarrhea, malaise/fatigue, difficulty in breathing, confusion, mechanical ventilation, vasopressor support, malnutrition and admission to High Dependency Unit had significant associations.</p><p><strong>Conclusion: </strong>Mortality was heightened among SRI patients who were older, required critical care, had chronic conditions and infected with SARS-CoV-2 suggesting need for early identification of these conditions to improve possible treatment outcomes.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126910"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mind the jingle: A call to consider construct validity of the 7C of vaccination readiness.","authors":"Mattis Geiger, Cornelia Betsch, Robert Böhm","doi":"10.1016/j.vaccine.2025.126843","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.126843","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126843"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between basal humoral immunogenicity and side effects after receiving the bivalent formulation of a mRNA-based vaccine.","authors":"Laura Pighi, Gian Luca Salvagno, Giuseppe Lippi","doi":"10.1016/j.vaccine.2025.126803","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.126803","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126803"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study on the inactivation and immunogenicity of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis vaccines prepared using different inactivants.","authors":"Yanna Wei, Jia Wang, Li Wang, Beibei Liu, Ting Yuan, Yanfei Yu, Guoqing Shao, Zhixin Feng, Thandeka Ntokozo Khoza, Qiyan Xiong","doi":"10.1016/j.vaccine.2025.126766","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.126766","url":null,"abstract":"<p><p>The present study aimed to investigate the optimal inactivants and inactivation conditions for preparing inactivated vaccines of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis. Mycoplasma inactivation was performed using formaldehyde, thimerosal, β-propiolactone (BPL), and binary ethylenimine (BEI) and compared. The results showed that M. hyopneumoniae was completely inactivated when incubated with 0.01 % formaldehyde for 24 h or 0.02 % formaldehyde for 12 h at 37 °C, with 0.0008 % thimerosal for 12 h at 37 °C, with 0.02 % BPL for 24 h or 0.1 % BPL for 12 h at 4 °C, or with 0.004 % BEI for 24 h or 0.5 % BEI for 12 h at 37 °C. M. hyorhinis was completely inactivated when incubated with 0.01 % formaldehyde for 24 h or 0.02 % formaldehyde for 12 h at 37 °C, with 0.004 % thimerosal for 24 h or 0.02 % thimerosal for 12 h at 37 °C, with 0.1 % BPL for 12 h at 4 °C, or with 0.004 % BEI for 24 h or 0.5 % BEI for 12 h at 37 °C. Next, the immunogenicity of the mycoplasmas after inactivation was evaluated by immunizing BALB/c mice. Immunization of mice with a high dose (10⁶ color-changing units [CCU] per dose) of M. hyopneumoniae and M. hyorhinis vaccines inactivated with all inactivants led to high levels of serum IgG antibodies. M. hyopneumoniae vaccines inactivated with formaldehyde induced significantly higher titers of antibodies than vaccines inactivated with other inactivants, whereas M. hyorhinis vaccines inactivated with BEI induced significantly higher titers of antibodies than vaccines inactivated with thimerosal. However, in mice immunized with a low dose of mycoplasmas (10⁴ CCU per dose), only M. hyopneumoniae vaccines inactivated with formaldehyde and BEI and M. hyorhinis vaccines inactivated with formaldehyde, BPL, and BEI led to significant levels of serum IgG antibodies. Among these groups, the antibody levels in the formaldehyde-inactivated vaccine group were higher than those in the other inactivant groups. This study provides a reliable basis for inactivation during large-scale production of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis inactivated vaccines.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126766"},"PeriodicalIF":0.0,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143044001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue vaccination and outbreaks: Bridging clinical diagnosis with genomic surveillance.","authors":"Marta Giovanetti, Eleonora Cella, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Svetoslav Nanev Slavov","doi":"10.1016/j.vaccine.2025.126755","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.126755","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126755"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda.","authors":"Paul D Kasaija, Fredrick Kabi, Jimmy Semakula, Ivan Kyakuwa, Marinela Contreras, Gabriela de la Fuente, Justus Rutaisire, Swidiq Mugerwa, Christian Gortázar, José de la Fuente","doi":"10.1016/j.vaccine.2024.126562","DOIUrl":"10.1016/j.vaccine.2024.126562","url":null,"abstract":"<p><p>After approval of the Subolesin-based anti-tick vaccine in Uganda, we completed a one-year follow-up evaluation study. The results showed significantly 2.1-5.0-fold higher anti-SUB IgG antibody titers in vaccinated cattle in Mbarara and Maruzi with vaccine effectiveness higher than 95 %. In Mbarara, total number of ticks were 0.8-fold lower in vaccinated cattle with a negative correlation tendency between anti-SUB antibody titers and tick counts. The CCHFV-seropositive cattle significantly decreased in 40 % in SUB-vaccinated animals with a significant positive correlation between CCHFV-seropositive cattle and the total number of ticks per animal and a negative correlation tendency between anti-SUB antibody titers and CCHFV-seropositive cattle. A boosting vaccine dose yearly after primary vaccination with three doses is sufficient to maintain protective antibody titers against ticks and tick-borne diseases affecting human and animal health. These results are relevant for implementation of anti-tick Subolesin-based vaccines in Uganda and other countries in Sub-Saharan Africa.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"44 ","pages":"126562"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.","authors":"Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, Natasha S Kelkar, Shilpee Sharma, Pieter Pannus, Alexandra Waegemans, Véronique Olislagers, Daphnée Georges, Emilie Dhondt, Margarida Braga, Leo Heyndrickx, Johan Michiels, Anaïs Thiriard, Anne Lemy, Thomas Baudoux, Marylène Vandevenne, Maria E Goossens, André Matagne, Isabelle Desombere, Kevin K Ariën, Margaret E Ackerman, Alain Le Moine, Arnaud Marchant","doi":"10.1016/j.vaccine.2024.126544","DOIUrl":"10.1016/j.vaccine.2024.126544","url":null,"abstract":"<p><strong>Background: </strong>Clinical risk factors of deficient immune responses to COVID-19 mRNA vaccination in SARS-CoV-2 naive hemodialysis recipients (HDR) have already been identified. Clinical factors influencing hybrid immunity induced by SARS-CoV-2 infection and vaccination in HDR have not been reported.</p><p><strong>Methods: </strong>A comprehensive analysis of antibody (Ab) and T cell responses to two doses of BNT162b2 mRNA vaccination was performed in 103 HDR, including 75 SARS-CoV-2 naive and 28 experienced patients, and in 106 healthy controls (HC) not undergoing HD, including 40 SARS-CoV-2 naive and 66 experienced subjects. Clinical risk factors associated with lower humoral and cellular immunity were analyzed in SARS-CoV-2 naive and experienced HDR by univariate and multivariate analyses.</p><p><strong>Results: </strong>Naive HDR had lower neutralizing and non-neutralizing antibody responses to vaccination than naive HC; lower vaccine responses were correlated with previous transplantation, immunosuppressive treatment, corticosteroid treatment, hypoalbuminemia, older age, hypertension, and negative response to hepatitis B vaccination. In contrast, vaccine responses of SARS-CoV-2 experienced HDR were similar to those of HC and were correlated with time between infection and vaccination and with previous transplantation, but not with the other risk factors associated with lower vaccine responses in naive HDR.</p><p><strong>Conclusion: </strong>COVID-19 vaccine responses are influenced by distinct risk factors in SARS-CoV-2 naive and experienced HDR. These observations have important implications for the understanding of vaccine-induced immunity and for the management of this vulnerable patient population.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"44 ","pages":"126544"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.","authors":"Qiang Wang, Liuqing Yang, Lan Li, Shixin Xiu, Min Yang, Xuwen Wang, Yuan Shen, Weibing Wang, Leesa Lin","doi":"10.1016/j.vaccine.2024.126570","DOIUrl":"10.1016/j.vaccine.2024.126570","url":null,"abstract":"<p><strong>Introduction: </strong>Our study aimed to assess parents' perceptions of respiratory syncytial virus (RSV) and their attitudes towards the RSV vaccine in China.</p><p><strong>Method: </strong>The cross-section study was performed between August 21 and November 15, 2023, in Jiangsu province, eastern China. We collected socio-demographics, awareness, knowledge, perceptions of susceptibility and severity of RSV, and attitudes towards RSV vaccine using online survey questionnaire from parents of child aged ≤14 years old. The chi-square test and logistic regression model to explore the associated factors.</p><p><strong>Results: </strong>A total of 2135 participants were included. About 26.0 % indicated that they had never heard of RSV (556/2135) and were unaware that infants and young children are at a high risk of contracting RSV (557/2135). The proportion of parents with a child under 1 year of age who were unaware of RSV was notably higher than that of parents with children in other age groups. 42.9 % of parents (916/2135) showed low level of perceived susceptibility of contacting RSV infection for their child. 70.6 % of parents (1508/2135) expressed their willingness to vaccinate their child against RSV. The most common reason for refusing the RSV vaccine was \"Concern about vaccine's safety or side effects.\" 60.8 % of participants (1299/2135) considered a price of the RSV vaccine below 200 CNY (28 USD) as acceptable.</p><p><strong>Conclusion: </strong>The parents, particularly those with younger children, exhibited limited awareness and knowledge regarding RSV infection. Our study also showed the potential role of vaccine price as a barrier to the future use of RSV vaccine in China.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"44 ","pages":"126570"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142756009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.","authors":"C E Gurry, J M Mwenda, A Nardone, S Cohuet, A Worwui, M Valenciano, H C Lewis, C S Wiysonge, R Katsande, R Mukaro, F Braka, A S Gueye, T Balde, I Bergeri, B Impouma","doi":"10.1016/j.vaccine.2024.126616","DOIUrl":"10.1016/j.vaccine.2024.126616","url":null,"abstract":"<p><p>Population-level vaccination with newly developed vaccines to respond to the COVID-19 pandemic created a need to monitor vaccine effectiveness (VE) in the context of emerging SARS-CoV-2 variants and changing epidemiology. WHO and partners launched the African Region Monitoring Vaccine Effectiveness (AFRO-MoVE) Network in March 2021 to assess the performance of COVID-19 vaccines in real-world conditions in Africa. The Network aimed to facilitate and support comparable COVID-19 vaccine effectiveness studies in the African region, to provide a platform of scientific expertise and infrastructure, encourage the use of robust similar study designs to enable pooling to produce regional VE estimates and to build a sustainable network of hospitals, institutions, and experts to evaluate vaccines against pandemic and endemic respiratory pathogens. In the two years since its inception, the network has coordinated VE studies in the region and provided technical guidance and generic protocols employing robust methodologies. It brought together over 200 experts, representing 22 African countries and 55 organisations, and strengthened capacities by hosting ten webinars and six technical workshops. Of the 55 partners organisations, 25 based in 13 countries collaborated on implementing VE studies in the region. AFRO-MoVE supported study implementation in two phases, first targeting COVID-19 vaccination priority groups, then the general population. The network provides technical and financial support to nine studies, including three cohort studies in health workers and adults with comorbidities, and six test-negative design studies evaluating VE against symptomatic and severe disease. A data platform was established for pooled regional estimates. The AFRO-MoVE Network can form a sustainable platform to provide data for evidence informed decisions and timely VE monitoring for existing and new vaccines against respiratory pathogens and other diseases in the African region. Further development and consolidation of the network's activities can enable rapid response to future epidemics and pandemics.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126616"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}